改良衰弱指数预测妇科肿瘤减灭术联合HIPEC术后并发症
该单中心前瞻性注册研究纳入2014至2020年141例接受肿瘤细胞减灭术(CRS)联合腹腔热灌注化疗(HIPEC)的晚期或复发妇科肿瘤患者,以改良衰弱指数(mFI)≥2定义衰弱。多因素分析显示mFI≥2与≥2级Accordion术后并发症显著增加相关(OR 9.4,95%CI 3.3–26.4,P<0.001)。
要点
- mFI≥2的衰弱患者≥2级并发症风险显著升高(OR 9.4)。
- 衰弱组再手术、ICU入住、急性肾损伤和呼吸衰竭发生率均更高。
- CRS联合HIPEC术前应进行衰弱筛查以辅助患者选择。
核心结论
- 改良衰弱指数(mFI)可预测妇科肿瘤患者CRS联合HIPEC术后≥2级并发症。
- 术前衰弱筛查可能有助于患者选择和改善术后结局。
研究设计与样本
- IRB批准的单中心前瞻性注册研究,查询2014年1月1日至2020年12月31日接受CRS联合HIPEC的晚期或复发妇科肿瘤女性。
- 共纳入141例女性,衰弱定义为mFI≥2。
- 采用Logistic回归评估mFI对≥2级Accordion术后并发症的影响。
主要发现
- 141例中非衰弱(mFI 0–1)占81.6%(n=115),衰弱(mFI≥2)占18.4%(n=26)。
- ≥2级并发症发生率:mFI=0为21.2%(n=14),mFI=1为26.5%(n=13),mFI=2为64.7%(n=11),mFI≥3为100.0%(n=9)。
- 非衰弱 vs 衰弱:再手术1.7% vs 11.5%(p=0.044),ICU入住13.2% vs 34.6%(p=0.018),急性肾损伤6.3% vs 30.8%(p=0.001),呼吸衰竭0.9% vs 19.2%(p<0.001)。
- 多因素分析中mFI≥2 vs mFI 0–1与≥2级并发症显著相关(OR 9.4,95%CI 3.3–26.4,p<0.001)。
- 年龄(OR 1.04,95%CI 1.00–1.09,p=0.07)、手术指征复发vs原发(OR 0.71,95%CI 0.30–1.7,p=0.44)、手术复杂度评分中/高vs低(OR 1.5,95%CI 0.67–3.5,p=0.31)与≥2级并发症无显著关联。
关键数值与推荐
- 衰弱定义:改良衰弱指数(mFI)评分≥2。
- 并发症分级采用Accordion分级,终点为≥2级并发症。
- mFI≥2 vs 0–1的≥2级并发症OR为9.4(95%CI 3.3–26.4,p<0.001)。
临床怎么用
- 对拟行CRS联合HIPEC的妇科肿瘤患者,术前可用mFI≥2识别衰弱高危人群。
- 衰弱患者术后需加强ICU、肾功能和呼吸功能监测。
- 衰弱筛查可辅助患者选择和术前优化。
局限性
- 单中心前瞻性注册研究,样本量141例,衰弱组仅26例。
- 原文摘要未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE(S): To evaluate the impact of frailty on postoperative complications following cytoreductive surgery (CRS) with hyperthermic intra-peritoneal chemotherapy (HIPEC) in women with advanced or recurrent gynecologic cancer. METHODS: An IRB-approved single-institution prospective registry was queried for women who underwent CRS with HIPEC for advanced or recurrent gynecologic cancer from 1/1/2014-12/31/2020. Frailty was defined as a modified Frailty Index (mFI) score of ≥2. Logistic regression was used to assess the impact of mFI upon the rate of moderate or higher (≥ grade 2) Accordion postoperative complications. RESULTS: Of 141 women, 81.6% (n = 115) were non-frail with mFI of 0-1 and 18.4% (n = 26) were frail with mFI ≥2. The incidence of ≥ grade 2 complications was 21.2% (n = 14) for mFI = 0, 26.5% (n = 13) for mFI = 1, 64.7% (n = 11) for mFI = 2 and 100.0% (n = 9) for patients with mFI ≥3. The incidence of re-operation (1.7% vs. 11.5%, p = 0.044), ICU admission (13.2% vs. 34.6%, p = 0.018), acute kidney injury (6.3% vs. 30.8%, p = 0.001), and respiratory failure (0.9% vs. 19.2%, p < 0.001) were significantly lower amongst non-frail vs. frail women. On multivariable analysis, mFI ≥2 was associated with significantly increased ≥ grade 2 complications versus mFI of 0-1 (OR 9.4, 95% CI 3.3, 26.4, p < 0.001). Age (OR 1.04, 95% CI 1.00, 1.09, p = 0.07), surgical indication (recurrent vs. primary) (OR 0.71, 95% CI 0.30, 1.7, p = 0.44) and Surgical Complexity Score of Intermediate or High vs. Low (OR 1.5, 95% CI 0.67, 3.5, p = 0.31) were not associated with ≥grade 2 complications. CONCLUSIONS: Frailty, defined by the modified frailty index, is predictive of ≥grade 2 postoperative complications following CRS with HIPEC in women with gynecologic cancer. Frailty screening before CRS with HIPEC may assist patient selection and improve postoperative outcomes.
引用
- Chambers LM, Chalif J, Yao M, et al. Modified frailty index predicts postoperative complications in women with gynecologic cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Gynecol Oncol. 2021. PMID: 34083027. doi:10.1016/j.ygyno.2021.05.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。